Recent evidence suggests that the net-benefit of aspirin in primary prevention is questionable, especially in lower risk individuals, and that careful selection of patients is needed based on patient preferences and after considering the potential risks and benefits of aspirin for each individual (ie, potential harm in patients > 70 years or patients at higher risk for bleeding).